Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $23.9 million.

  • Ligand Pharmaceuticals' Tax Provisions rose 276482.59% to $23.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year increase of 610.12%. This contributed to the annual value of $6.6 million for FY2024, which is 3344.17% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Tax Provisions stood at $23.9 million for Q3 2025, which was up 276482.59% from $6.4 million recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Tax Provisions peaked at $38.7 million during Q4 2022, and registered a low of -$13.5 million during Q2 2024.
  • Moreover, its 5-year median value for Tax Provisions was $1.5 million (2021), whereas its average is $4.0 million.
  • Its Tax Provisions has fluctuated over the past 5 years, first crashed by 162996.59% in 2024, then surged by 276482.59% in 2025.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Tax Provisions stood at $4.1 million in 2021, then skyrocketed by 847.43% to $38.7 million in 2022, then tumbled by 102.82% to -$1.1 million in 2023, then crashed by 643.54% to -$8.1 million in 2024, then surged by 394.18% to $23.9 million in 2025.
  • Its last three reported values are $23.9 million in Q3 2025, $6.4 million for Q2 2025, and -$7.7 million during Q1 2025.